• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Endocyte, Inc. is a biopharmaceutical company, which engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN.
| Market Cap | 1.969 Billion | Shares Outstanding | 82.089 Million | Avg 30-day Volume | 2.218 Million |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.5 |
| Price to Revenue | 11159.6311 | Debt to Equity | 0.0 | EBITDA | -43.727 Million |
| Price to Book Value | 4.199 | Operating Margin | -33441.043300000005 | Enterprise Value | 1.114 Billion |
| Current Ratio | 45.775 | EPS Growth | 0.522 | Quick Ratio | 44.856 |
| 1 Yr BETA | 0.3885 | 52-week High/Low | 0.0 / | Profit Margin | -31643.3198 |
| Operating Cash Flow Growth | -12.7304 | Altman Z-Score | 108.6463 | Free Cash Flow to Firm | -34.894 Million |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
No longer subject to file | 2018-12-21 | 0 | |
|
No longer subject to file | 2018-12-21 | 0 | |
|
No longer subject to file | 2018-12-21 | 0 | |
|
No longer subject to file | 2018-12-21 | 0 | |
|
No longer subject to file | 2018-12-21 | 0 | |
|
No longer subject to file | 2018-12-21 | 0 | |
|
LEAMON CHRISTOPHER P VICE PRESIDENT OF RESEARCH |
|
No longer subject to file | 2018-12-21 | 0 |
|
SHERMAN MICHAEL A. PRESIDENT AND CEO |
|
No longer subject to file | 2018-12-21 | 0 |
|
LOW PHILIP S CHIEF SCIENCE OFFICER |
|
No longer subject to file | 2018-12-21 | 0 |
|
TAYLOR BETH VP FINANCE & CHIEF ACCTG OFF |
|
No longer subject to file | 2018-12-21 | 0 |
|
No longer subject to file | 2018-12-21 | 0 | |
|
PARKER KATHERINE VP OF HUMAN RESOURCES |
|
No longer subject to file | 2018-12-21 | 0 |
|
ARMOUR ALISON A. CHIEF MEDICAL OFFICER |
|
No longer subject to file | 2018-12-21 | 0 |
|
ANDRIOLE MICHAEL T. CHIEF FINANCIAL OFFICER |
|
No longer subject to file | 2018-12-21 | 0 |
|
CHELIUS ERIK C. VICE PRESIDENT CMC |
|
No longer subject to file | 2018-12-21 | 0 |
|
MCAVOY DAVID R. GENERAL COUNSEL |
|
No longer subject to file | 2018-12-21 | 0 |
|
7,800 | 2017-05-04 | 0 | |
|
18,271 | 2017-05-04 | 0 | |
|
7,800 | 2017-05-04 | 0 | |
|
BRINKLEY MICHAEL A. VICE PRESIDENT OF QUALITY |
|
23,486 | 2017-02-04 | 0 |
|
No longer subject to file | 2016-06-24 | 0 | |
|
HARPER SCOT VP OF CLINICAL OPERATIONS |
|
22,535 | 2016-02-04 | 0 |
|
NGUYEN BINH VP OF MEDICAL AFFAIRS |
|
28,359 | 2015-03-03 | 0 |
|
LOVEJOY CHANDRA D VP OF REGULATORY AFFAIRS |
|
6,250 | 2014-08-11 | 0 |
|
RITTER ALLEN R VP OF MANUFACTURING/CMC |
|
34,282 | 2014-04-09 | 0 |
|
MEEK DAVID D. CHIEF COMMERCIAL OFFICER |
|
7,500 | 2014-02-06 | 0 |
|
No longer subject to file | 2012-12-11 | 0 | |
|
0 | 2012-05-31 | 0 | |
|
SANDERLING VENTURE PARTNERS V, LP SANDERLING VENTURE PARTNERS VI CO INVESTMENT FUND LP SANDERLING VENTURE PARTNERS V CO INVESTMENT FUND, LP SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP SANDERLING V BETEILIGUNGS GMBH & CO KG SANDERLING VI LIMITED PARTNERSHIP |
|
871,461 | 2011-12-20 | 0 |
|
0 | 2011-05-26 | 0 | |
|
0 | 2011-05-26 | 0 | |
|
MESSMANN RICHARD A VP OF MEDICAL AFFAIRS |
|
0 | 2011-04-14 | 0 |
|
No longer subject to file | 2011-02-09 | 0 | |
|
SANDERLING VENTURE PARTNERS V, LP SANDERLING VENTURE PARTNERS VI CO INVESTMENT FUND LP SANDERLING VENTURE PARTNERS V CO INVESTMENT FUND, LP SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP SANDERLING V BETEILIGUNGS GMBH & CO KG |
|
1,480,595 | 2011-02-09 | 0 |
|
PENSION FUND OF THE CHRISTIAN CHURCH (DISCIPLES OF CHRIST) INC |
|
3,283,132 | 2011-02-09 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
